YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Dr Reddys Laboratories

Dr Reddys Laboratories

BSE: 500124|NSE: DRREDDY|ISIN: INE089A01023|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Nov 26, 16:00
4744.90
152.4 (3.32%)
VOLUME 40,682
LIVE
NSE
Nov 26, 15:59
4750.90
159.3 (3.47%)
VOLUME 1,072,273
News on Dr Reddys Laboratories
Select Year: 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Dr Reddys Labs Standalone September 2021 Net Sales at Rs 3,823.40 crore, up 14.27% Y-o-Y

8.46 am | 09 Nov 2021 |  Source: Moneycontrol.com

NULL...

Dr Reddys Labs Consolidated September 2021 Net Sales at Rs 5,786.90 crore, up 17.84% Y-o-Y

7.11 pm | 08 Nov 2021 |  Source: Moneycontrol.com

NULL...

Dr Reddys Labs Standalone September 2021 Net Sales at Rs 3,823.40 crore, up 14.27% Y-o-Y

7.00 pm | 08 Nov 2021 |  Source: Moneycontrol.com

NULL...

Buy Dr Reddy’s Labs; target of Rs 5470: Motilal Oswal

1.35 pm | 03 Nov 2021 |  Source: Moneycontrol.com

Motilal Oswal is bullish on Dr Reddy’s Labs recommended buy rating on the stock with a target price of Rs 5470 in its research report dated October ...

Dr Reddy’s: Aced by emerging markets' growth

11.32 am | 01 Nov 2021 |  Source: Moneycontrol.com

While DRL is hit by pricing erosion in the US business, potential growth in the limited competition products underlines a positive outlook...

What should investors do with Dr Reddy’s Laboratories post Q2 results; Buy, sell or hold?

10.11 am | 01 Nov 2021 |  Source: Moneycontrol.com

The revenues came in higher by 18% at Rs 5,763 crore for the quarter, compared to Rs 4,897 crore in the same period last year....

Dr Reddy’s Q2 profit rises 30% to Rs 992 crore, revenue increases 18%

2.23 pm | 29 Oct 2021 |  Source: Moneycontrol.com

While we continue to strengthen our core businesses of generics and APIs, we are also making investments in our long-term growth drivers and deeper in...

Dr Reddy’s Q2 Results Preview: Revenue expected to increase 4-5%, PAT to decline 15%

7.59 am | 29 Oct 2021 |  Source: Moneycontrol.com

Kotak Institutional Equities expects North America business (including Canada) to increase by $11 million q-o-q to $246 million, and forecasts...

Dr Reddy’s Q2 Results Preview: Revenue expected to increase 4-5%, PAT to decline 15%

7.59 am | 29 Oct 2021 |  Source: Moneycontrol.com

Kotak Institutional Equities expects North America business (including Canada) to increase by $11 million q-o-q to $246 million, and forecasts...

Dr Reddy's Lab receives USFDA approval to market Lenalidomide capsule

3.04 pm | 19 Oct 2021 |  Source: PTI

The company’s product is the generic version of Revlimid (lenalidomide) capsules....

Dr Reddy's gets FDA nod for generic Revlimid; Enjoys 180 days exclusivity

12.16 pm | 19 Oct 2021 |  Source: PTI

According to a press release issued by the city-based drug maker, the FDA approved Lenalidomide capsules in 2.5 mg and 20 mg strengths and gave tentat...

Dr. Reddy’s Laboratories Q2 PAT may dip 11.5% YoY to Rs 752.2 cr: Prabhudas Lilladher

5.39 pm | 06 Oct 2021 |  Source: Moneycontrol.com

Net Sales are expected to increase by 4.9 percent Y-o-Y (up 4.2 percent Q-o-Q) to Rs 5,153.4 crore, according to Prabhudas Lilladher....

Buy Dr Reddy’s Laboratories: target of Rs 5900: Sharekhan

1.03 pm | 07 Sep 2021 |  Source: Moneycontrol.com

Sharekhan is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5900 in its research report dated ...

Hold Dr Reddy’s Laboratories: target of Rs 5250: ICICI Direct

11.27 am | 02 Aug 2021 |  Source: Moneycontrol.com

ICICI Direct recommended hold rating on Dr Reddy’s Laboratories with a target price of Rs 5250 in its research report dated July 28, 2021....

Dr Reddy’s: Growth story remains intact; margins key monitorable

11.43 am | 28 Jul 2021 |  Source: Moneycontrol.com

Dr Reddy's margins are likely to be weighed by recurring investments - digitization, brand building exercise & elevated R&D - in near to medium te...

Dr Reddys Labs Consolidated June 2021 Net Sales at Rs 4,945.10 crore, up 11.72% Y-o-Y

7.22 pm | 27 Jul 2021 |  Source: Moneycontrol.com

NULL...

Dr Reddys Labs Standalone June 2021 Net Sales at Rs 3,433.50 crore, up 5.83% Y-o-Y

7.11 pm | 27 Jul 2021 |  Source: Moneycontrol.com

NULL...

Dr Reddy's Q1 results: Profit falls 1.5% to Rs 570.8 crore, revenue increases 11.4%

11.39 am | 27 Jul 2021 |  Source: Moneycontrol.com

Dr Reddy's Q1 results: Earnings miss expectations as profit was estimated at Rs 700 crore on a revenue of Rs 4,991.4 crore. Global generics busine...

Dr. Reddy’s Laboratories Q1 PAT seen up 10.2% YoY to Rs 655.4 cr: KRChoksey

11.37 am | 13 Jul 2021 |  Source: Moneycontrol.com

Net Sales are expected to increase by 19.1 percent Y-o-Y (up 10.5 percent Q-o-Q) to Rs 5,270.1 crore, according to KRChoksey....

Dr Reddy’s Q1 PAT seen up 5.4% YoY to Rs 626.7 cr: ICICI Direct

7.56 pm | 12 Jul 2021 |  Source: Moneycontrol.com

Net Sales are expected to increase by 10.9 percent Y-o-Y (up 3 percent Q-o-Q) to Rs 4,910.8 crore, according to ICICI Direct....

1 2
Quick Links for Dr Reddys Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.